Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anruize (HS022) + vinorelbine vs Herceptin + vinorelbine in HER2-positive metastatic breast cancer
CTR20180362Phase 3Completed
- Sponsor
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of anlotinib, trastuzumab in breast cancer, sponsored by Zhejiang Hisun Pharmaceutical Co., Ltd.. Started Apr 2018; status: completed.
02
Drugs
anlotinibtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20180362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180362.